2022 World Conference on Lung Cancer (ePosters)-EP16.03-027. Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC

Pdf Summary

This study evaluated the use of next-generation sequencing (NGS) on tumour samples in non-small-cell lung cancer (NSCLC) patients. The researchers used the TruSight-Oncology-500 (TSO500) panel to assess the molecular profile and clinical outcomes in a cohort of patients. The TSO500 panel covers coding regions of 523 genes for small variants, 59 genes for copy number alterations, and 55 genes for fusions and splice variants. The frequency of actionable genomic alterations (GA) and access to targeted therapy were assessed.<br /><br />The results showed that actionable GA were detected in 31.5% of patients using the TSO500 panel. Patients with actionable GA who received targeted therapy had significantly longer overall survival. The study included 207 patients with NSCLC, with a median age of 63 years. The majority of patients were male and had adenocarcinoma histology. The most common single biomarker tests performed were for EGFR, ALK, and ROS1.<br /><br />The study also found that the TSO500 panel was an efficient diagnostic tool for screening for actionable GA in NSCLC patients. It identified druggable GA in a significant proportion of patients, emphasizing the importance of ensuring access to NGS and targeted therapy in this patient population.<br /><br />Additionally, the study analyzed the frequency of RNA libraries failure according to the type of sample. Biopsy samples had a failure rate of 3.8%, cytology samples had a failure rate of 2.1%, and surgical samples had a higher failure rate of 17.1%. The age of the sample was significantly higher when RNA libraries failed.<br /><br />In conclusion, the TSO500 NGS panel is effective in identifying actionable GA in NSCLC patients and plays a crucial role in guiding targeted therapies. The study highlights the need for access to NGS and targeted therapy in patients with NSCLC to improve clinical outcomes.

Asset Subtitle

Miguel Mosteiro Lamas

Meta Tag

Speaker Miguel Mosteiro Lamas

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

next-generation sequencing

tumour samples

TruSight-Oncology-500 panel

genomic alterations

targeted therapy

overall survival

biomarker tests

diagnostic tool

NSCLC patients

RNA libraries failure